Blumenthal Paul D, Gemzell-Danielsson Kristina, Marintcheva-Petrova Maya
Family Planning Services and Research, Department of Obstetrics and Gynecology, Stanford University, Stanford, CA, USA.
Eur J Contracept Reprod Health Care. 2008 Jun;13 Suppl 1:29-36. doi: 10.1080/13625180801960012.
To evaluate the tolerability and clinical safety of the subdermal, long-acting hormonal contraceptive Implanon.
This integrated safety analysis included 11 international studies concerning Implanon (68 mg etonogestrel) of which 10 had a duration of at least two years. Assessments included reports of adverse events (AEs), reasons and rates of discontinuation, insertion/removal complications, and the condition of the implant site. Metabolic and coagulation parameters are briefly discussed to fully describe the clinical safety profile.
In total 942 women were exposed to Implanon for 24,679 cycles over the course of one to five years. The overall discontinuation rate was 32.7%; the most frequently reported reasons for discontinuation were adverse events (13.9%), bleeding irregularities (10.4%), and planning pregnancy (4.1%). The most commonly reported drug-related AE was headache (15.3%); however, headache was reported in only 1.6% of women as a reason for discontinuation. Insertion and removal times for Implanon were short with few complications, none of which were major. From earlier studies it is known that treatment with Implanon has little effect on metabolic and coagulation parameters.
Implanon is a well-tolerated and safe method of long-acting hormonal contraception for women.
评估皮下埋植长效激素避孕药依伴侬的耐受性和临床安全性。
这项综合安全性分析纳入了11项关于依伴侬（68毫克依托孕烯）的国际研究，其中10项研究的持续时间至少为两年。评估内容包括不良事件报告、停药原因和比例、植入/取出并发症以及植入部位状况。简要讨论了代谢和凝血参数以全面描述临床安全性概况。
共有942名女性在1至5年的时间里使用依伴侬达24,679个周期。总体停药率为32.7%；最常报告的停药原因是不良事件（13.9%）、出血不规律（10.4%）和计划妊娠（4.1%）。最常报告的与药物相关的不良事件是头痛（15.3%）；然而，只有1.6%的女性因头痛而停药。依伴侬的植入和取出时间短，并发症少，且均非严重并发症。从早期研究可知，使用依伴侬治疗对代谢和凝血参数影响很小。
依伴侬是一种耐受性良好且安全的女性长效激素避孕方法。
